İlhami ÇELİK, Mustafa CİHANGİROĞLU, MEHMET ÇABALAK, Erol SEVİM, Ayhan AKBULUT, S. Sırrı KILIÇ

Hastane kaynaklı koagülaz negatif stafilokoklarda fosfomisin duyarlılığı metisilin direnci ve slaym yapımı ilişkisi

Hastane infeksiyonu etkeni olarak izole edilen 50 koagülaz negatif stafilokok susunda disk difüzyon yöntemi ile fosfomisin ve metisilin duyarlılığı, Kongo kırmızılı ağar yöntemiyle slaym oluşumu araştırılmıştır. Gerek NCCLS'de gerekse diğer standartlarda stafilokoklar için fosfomisinin zon çapı limitleri konusunda bir kriter bulunmamaktadır. Fosfomisin için median zon çapı çalışmamızda 32 mm (aralık: 18-64 mm) olarak saptanmış ve çeşitli çalışmalarda kullanılan kriterlere göre suşlarımızdafosfomisine direnç bulunmadığı kanaatine varılmıştır. Çalışmaya alınan suşlann 10'u metisiline duyarlı, 40'ı dirençli; 23'U slaym negatif, 27'si slaym pozitif bulunmuştur. Fosfomisinle alınan inhibisyon zon çapları ile metisilin direnci veya slaym oluşturma arasında, metisilin direnci ile slaym oluşturma arasında, fosfomisinle alınan median zon çapı altında ve üstünde zon veren suşlarla metisilin direnci veya slaym oluşturma arasında anlamlı bir ilişki bulunmamıştır. Stafilokok infeksiyonlarmın tedavisinde fosfomisinden yararlanılması konusunda daha kapsamlı çalışmalara gereksinim vardır.

Anahtar Kelimeler:

Staphylococcus, Fosfomisin, İlaç direnci, mikrobiyal, Çapraz enfeksiyon, Mikrobiyal duyarlılık testleri

Susceptibility to fosfomycin, methicilin resistance and slime production in coagulase negative staphylococci isolated from hospital acquired infections

Fosfomycin and methicillin susceptibilities were investigated by disk diffusion method and slime production was investigated by Congo red agar plate in 50 coagulase negative staphylococci isolated from hospital acquired infections. There is no criteria for susceptibility of staphylococci to fosfomycin neither in NCCLS nor in other standards. Fosfomycin zone diameters were established in our study as a median 32 mm (range: 18-64 mm), and according to the criteria used in some other papers, it is concluded that there is no fosfomycin-resistance in our strains. Ten strains were found susceptible to methicillin and 40 resistant; 23 strains were found slime negative and 27 positive. No significant relationship was found between the fosfomycin inhibition zones and methicillin resistance or slime production, between methicillin resistance and slime production, between methicillin resistance or slime production and the strains with inhibition zones under or over the median zone for fosfomycin. More comprehensive studies are needed to make use of fosfomycin in the treatment of infections due to staphylococci.

Keywords:

Staphylococcus, Fosfomycin, Drug Resistance, Microbial, Cross Infection, Microbial Sensitivity Tests,

PDF

___

1. Allerberger F,Klare I: In vitro activity of fosfomycin against vancomycinresistant enterococci, J Antimicrob Chemother 1999;43(2):211-7.
2. Barry AL, Pfaller MA, Fuchs PC Tenover FC, Reller LB, Allen SD, Hardy DJ,Gerlach EH: Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine, Eur J Clin Microbiol Infect Dis 1993;12(5):352-6.
3. Baussard P, Pithsy A, DevleeschovwerMJ: Relationship between slaym production, antibiotic sensitivity and the phagotype of coagulase-negative staphylococci, J Clin Pharm Ther 1993;18(4):271-4.
4. Brandt CM, Rouse MS, Tallan BM, Laue NW,Wilson WR, Steckelberg JM: Effective treatment or cephalosporin-rifampicin combinations against cryptic methicillin-resistant ß-lactamase-producing coagulase-negative staphylococcal experimental endocarditis,AntimicrobAgents Chemother 1995;39(8):1815-9.
5. Chisena S, Marconato R, Cantoni G, Zappa M, InzaghiA, Pasargiklian I, Mascheroni E, Ranzi ML, Longo T: Importance of Staphylococcus epidermidis in the bacterial colonization of abdominal drains in surgical patients, Minerva Chir 1991;46(6):269-72.
6. Comité de l'antibiogramme de la Société française de microbiologie: communiqué 2005.
7. Diaz-Mitoma F, Harding GK, Hoban DJ, Roberts RS, Low DE: Clinical significance of a test for slaym production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci, J Infect Dis 1987;156(4):555-60.
8. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M; SENTRY Partcipants Group: Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and theWestern Pacific region for the SentryAntimicrobial Surveillance Program, 1997-1999, Clin Infect Dis 2001;32(Suppl 2): 114-32.
9. Domingue G, Ellis B, DasguptaM, Costerton JW: Testing antimicrobial susceptibilities of adherent bacteria by amethod that incorporates guidelines of the National Committee for Clinical Laboratory Standards, J Clin Microbiol 1994;32(10):2564-8.
10. Dunne WM,MasonEO,Kaplan SL:Diffusion of rifampicin and vancomycin through a Staphylococcus epidermidis biofilm,Antimicrob Agents Chemother 1993;37(12):2522-6.
11. Elçi S, Gül K, Öğel F, Suay A, Mete Ö: Koagülaz negatif stafilokoklarda slaym oluşumunun ve antibiyotik direncinin saptanması, İnfeksiyon Derg 1996;10(3):203-6.
12. Forsgren A, Walder M: Antimicrobial acivity of fosfomycin in vitro, J Antimicrob Chemother 1983;11(5):467-71.
13. Fosse T, David MF, Duluc F, Darmusey D, Tamalet C, Toga B: In vitro study of the cefamandole-fosfomycin combination against methicillinresistant staphylococci, Pathol Biol 1984;32(5):528-31.
14. Freeman DJ, Falkiner FR:Coagulase-negative staphylococci and continuous peritoneal ambulatory dialysis, Rev Med Microbiol 1991;2(2):98-104.
15. Garcia-Rodriguez JA, Trujillano Martin I, Baquero F,Cisterna R, Gobernado M, Linares F,Martin-Luengo F, Piedrola G: In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study, J Chemother 1997;9(6):394-402.
16. Grimm H, Haag R: Susceptibility testing with fosfomycin in an agar diffusion test on Mueller-Hinton agar, Immun Infekt 1982;10(4):159-63.
17. Guerin F, Buu-Hoi A, Mainardi JL, Kac G, Colardelle N, Vaupre S, Gutmann L, Podglajen I:Outbreak ofmethicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital, J Clin Microbiol 2000;38(8):2985-8.
18. Günaydın M, Leblebicioğlu H, Saniç A, Pirinççiler M: Koagülaz-negatif stafilokoklarda slaymyapımı ve antibiyotik direnci ile ilişkisi,Mikrobiyol Bült 1995;29(1):26-31.
19. Hamilton-Miller JM: In vitro activity of fosfomycin against 'problem' gram-positive cocci, Microbios 1992;71(287):95-103.
20. Hara T, Araake M, Tsuruoka T, Watabe H: Antimicrobial activity of fosfomycin against beta-lactamase-producing methicillin-sensitive Staphylococcus aureus and methicillin-sensitive coagulase-negative staphylococci, Jpn J Antibiot 2003;56(2):142-7.
21. Hara T, Araake M, Watabe H: Antibacterial activities of fosfomycin against several fresh clinical isolates-Comparison of the test methods for antibacterial activity, Jpn J Antibiot 2002;55(6):844-54.
22. Kahan FM, Kahan JS, Cassidy PJ, Kropp H: The mechanism of action of fosfomycin, Ann New York Acad Sci 1974;235:364-85.
23. KristinssonKG, SpencerRC, BrownCB:Clinical importance of production of slaym by coagulase-negative staphylococci in chronic ambulatory peritoneal dialysis, J Clin Pathol 1986;39(1):117-8.
24. National Nosocomial Infections Surveillance (NNIS) System Report: Data summary from January 1990-May 1999, issued June 1999, Am J Infect Control 1999; 27(6):520-32.
25. NCCLS: Performance standards for antimicrobial disk susceptibility tests, 7th ed. Approved standard M2-A7. NCCLS, Wayne, Pa (2003).
26. Nourizadeh E, Sultan N: Koagülaz-negatif stafilokoklarda slaym (slaym) faktör yapımının çeşitli yöntemlerle gösterilmesi, İnfeksiyon Derg 1993; 7(1-2):31-4.
27. Peters G, von Eiff C, Herrmann M: The changing pattern of coagulasenegative staphylococci as infectious pathogens, Curr Opin Infect Dis 1995;8(Suppl 1):12-9.
28. PfallerMA, BarryAL, Fuchs PC: Evaluation of disk susceptibility testing of fosfomycin tromethamine, Diagn Microbiol Infect Dis 1993;17(1):67-70.
29. Portier H, Kazmierczak A, Lucht F, Tremeaux JC, Chavanet P, Duez JM: Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections, Infection 1985; 13(Suppl 1):S123-8.
30. Quentin C, Saivin S, Lafferriere C, Noury P, Bebear C: In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: A study by the time-kill curve method, Drugs Exp Clin Res 1987;13(4):219-24.
31. Vogt K, Rauhut A, Trautmann M, Hahn H: Comparison of fosfomycin and teicoplanin in serum bactericidal activity against staphylococci, Arzneimittelforschung 1995;45(8):894-7.